COA Meeting Highlights

A survey of oncology practices participating in the Centers for Medicare & Medicaid Services (CMS) Oncology Care Model (OCM) revealed that a “surprising” number of practices are willing to enter into a 2-sided risk arrangement, according to Bo Gamble, Director, Strategic Practice Initiatives, Community Oncology Alliance (COA). Read More ›

Social distancing, stay-at-home orders, and “the new normal.” We are all adapting to the changes brought about by COVID-19, but what does it mean for cancer care? At the virtual 2020 Community Oncology Alliance (COA) Community Oncology Conference, Bo Gamble, Director, Strategic Practice Initiatives, COA, asked a panel of experts to predict how the current climate will shape challenges for community oncologists in the future.

Read More ›

A Medically Integrated Pharmacy Care (MIPC) model represents the true integration of pharmaceutical and medical oncology care. At the virtual 2020 Community Oncology Alliance (COA) Community Oncology Conference, Jim Schwartz, RPh, Executive Director, Pharmacy Operations, Texas Oncology, Dallas, discussed this model, which he said provides clarity of focus around complex disease states.

Read More ›

Breast cancer doctors got it right a long time ago when they began characterizing malignancies with classifications such as hormone-receptor and HER2 status, according to Alexander Spira, MD, PhD, FACP, Medical Oncologist, Virginia Cancer Specialists, Fairfax.

Read More ›


The first oncology biosimilar was approved in the United States in 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, the University of Texas at Austin. Read More ›


Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: